Month: March 2021

PLANO, Texas., March 29, 2021 (GLOBE NEWSWIRE) — DZS Inc. (NASDAQ: DZSI), a global leader of packet-based mobile transport, broadband access, network orchestration and cloud-native automation solutions, today announced plans to host its first DZS Horizons21 Investor & Analyst Day on May 13, 2021 beginning at 9:00am CT. This virtual event will provide investors an in-depth view of the management team’s vision and innovation focus, as well as share insights on market trends, core DZS platforms and product portfolios, the financial outlook and insights from key customers and industry luminaries. Members of the DZS executive leadership team presenting will include:President and Chief Executive Officer, Charlie Vogt Chief Financial Officer, Tom Cancro Chief Technical Officer, Andrew Bender Vice President of Product Line Management,...

KEY MESSAGESDevon provided guidance for the first quarter and full-year 2021, adjusted for weather and an asset sale Severe winter weather is estimated to reduce first-quarter production by 8 percent Guidance excludes WPX results prior to the acquisition close date of Jan. 7, 2021 Sale of Wind River asset in Wyoming is expected to reduce 2021 oil production by 2,000 barrels per dayOKLAHOMA CITY, March 29, 2021 (GLOBE NEWSWIRE) — Devon Energy Corp. (NYSE: DVN) today provided guidance for the first quarter and full-year 2021 that incorporates the operational impact from recent winter weather and a minor asset sale. The company has restored its production to pre-storm levels and expects the weather-related downtime to be confined to the first quarter. First-quarter production is estimated to be reduced by 8 percent due to the impact...

GREENWOOD VILLAGE, Colo., March 29, 2021 (GLOBE NEWSWIRE) — Advanced Emissions Solutions, Inc. (NASDAQ: ADES) (the “Company” or “ADES”), the parent company of ADA-ES, Inc. and ADA Carbon Solutions, LLC (collectively, “ADA”), today announced a price increase, effective April 1, 2021 or as contract terms permit, on all activated carbon products and front-end coal additives. The increase will vary from 10% to 15% depending on the specific product, grade, and application. Throughout the COVID-19 Global Pandemic, our team has remained focused on continuing to meet the needs of our customers reliably and consistently. We have adapted our processes, improved our safety protocols, and worked closely to maintain a robust supply chain. These price increases have become necessary due to increases in raw...

-NEObody™ product candidate ADG116 has been well tolerated in ongoing Phase 1 clinical trial- -Promising pharmacodynamic biomarker signals demonstrate clinical proof of mechanism--Poised for global expansion- SAN FRANCISCO and SUZHOU, China, March 29, 2021 (GLOBE NEWSWIRE) — Adagene Inc. (Nasdaq: ADAG), a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based immunotherapies, today announced the interim dose-escalation data up to 0.3 mg/kg in its ongoing Phase 1 clinical trial in Australia evaluating the safety and tolerability of ADG116 in patients with advanced/metastatic solid tumors. ADG116 is a fully human, anti-CTLA-4 monoclonal antibody (mAb), designed to target a unique conserved epitope of CTLA-4 and utilizes Adagene’s proprietary NEObody...

-新表位抗体（NEObody™) 候选药物ADG 116在当前I期临床试验中显示出良好的耐受性-– ADG 116药理机制的早期临床验证支持其全球临床试验扩展- 中国苏州和美国旧金山, March 29, 2021 (GLOBE NEWSWIRE) — 天演药业（纳斯达克股票代码：ADAG）是一家平台驱动的临床阶段生物制药公司，致力于发现并开发以原创抗体为基石的新型癌症免疫疗法。公司今日公布了其正在澳大利亚进行的旨在评估ADG 116剂量递增的I期临床试验在晚期 / 转移性实体瘤患者中安全性和耐受性的中期数据（剂量递增至0.3 mg/kg）。ADG116是一款全人源抗CTLA-4单克隆抗体（mAb），凭借天演原创的新表位抗体平台技术靶向CTLA-4抗原的独特保守表位，旨在通过其全新的作用机制平衡安全性和有效性：ADG116通过部分阻断CTLA-4配体结合来维持其原有的生理功能，以及在肿瘤微环境（TME）中强力的抗体依赖细胞介导毒作用（ADCC）来清除调节性T细胞（Treg）。 I期临床试验的中期数据：安全性：对迄今为止生成的所有安全性数据的分析表明，ADG116在10多名患者中均显示出良好的耐受性，没有剂量限制性毒性或意外的安全性信号。同时，未观察到与药物相关的3级和4级毒性。 药理作用：在ADG116的用药患者中观察到CD8+和CD4+ TEM / Treg比值呈剂量依赖性变化，是免疫激活的重要药效学（PD）生物标志物。尤其是一名先前对帕博利珠单抗（pembrolizumab）治疗后（> 25个周期）耐药的患者，在接受ADG116给药后出现T细胞和NK细胞稳步地增加，以及CD8+ TEM / Treg比值的显著增加。该患者1级瘙痒的临床症状是治疗相关且与ADG116治疗的免疫介导作用一致。 药代动力学：ADG116的半衰期是在IgG1抗体的正常范围内。 药理机制的临床验证：I期剂量递增数据在临床上验证了ADG116靶向CTLA-4的机制，与临床前观察到的ADG116从0.03...

Kiruna, March 29, 2021 JANUARY – DECEMBER 2020Net profit for the period amounted to 6,909 (-14,552) KSEK, primarily based on a 20 MSEK capital gain deriving from a settlement of a future financial obligation to Sunstone Metals Ltd Earnings per share was 0.01 (-0.03) SEK Capitalized exploration assets at the end of the period amounted to 344,655 (303,438) KSEK, primarily based on significant core drillings and project development in Viscaria Copper Project Shareholders’ equity at the end of the period amounted to 296,802 (264,317) KSEK Total assets at the end of the period were 347,823 (333,291) KSEK The cash flow during the period was -18,146 (17,713) KSEKOCTOBER – DECEMBER 2020Net profit for the period amounted to 16,213 (-3,595) KSEK Earnings per share was 0.03 (-0.01) SEK The cash flow during the period was -11,713 (3,234) KSEKSIGNIFICANT...